Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's prosecution profile is highly focused, featuring 1 distinct examiner and 1 distinct art unit. This structure implies that all current patent examination activity is centralized within one technical division. Such concentration can be beneficial for ensuring that the technical disclosures are interpreted consistently by the patent office, reducing the risk of conflicting requirements from different examiners.
The busiest examiner for the portfolio is TAYLOR, LIA ELAN, who is responsible for 1 busiest examiner pending office action. This single action accounts for the total of 1 pending office action for the company. With only 1 distinct art unit involved, the company's current legal strategy at the patent office is concentrated on this specific examiner's review. This alignment allows the applicant to develop a more targeted response to the 1 busiest examiner pending office action, focusing on the technical nuances of the Biotechnology & Pharmaceuticals field as understood by this examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TAYLOR, LIA ELAN | 1 | 64.4% | +29.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17251695 | COMBINATION OF FACTOR VII AND AN ANTI-FACTOR IX/X BISPECIFIC ANTIBODY | TAYLOR, LIA ELAN | 49d overdue |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17251695 | COMBINATION OF FACTOR VII AND AN ANTI-FACTOR IX/X BISPECIFIC ANTIBODY | TAYLOR, LIA ELAN | 1641 | §103 | Final Rejection | 49d overdue | Pending | Dec 11, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial